Who Owns Axsome Therapeutics?
Axsome Therapeutics is a public company, so ownership sits with shareholders, not one parent. Founded in 2012 and public since 2015, it is led today through Nasdaq-listed governance and outside investors.
The biggest ownership question is who holds the most voting power and how that shapes control. For a quick market view, see Axsome Balanced Scorecard.
Who Founded Axsome?
Founders and early ownership of Axsome Therapeutics started with Herriot Tabuteau, who remains the most visible individual owner and the founder-CEO. Today, Axsome Therapeutics ownership is public, with no family, state, private equity, or parent-company control.
Founder-led start
Herriot Tabuteau founded Axsome Therapeutics and still anchors the Axsome Therapeutics owner structure. That makes him the key name in any review of Axsome Therapeutics insider ownership.
Public ownership now
Who owns Axsome Therapeutics today? Public shareholders do. The stock ownership breakdown is spread across insiders, institutions, and other market holders, not a single controlling block.
Institutional weight
Axsome Therapeutics institutional ownership matters because large funds often shape votes on directors and pay. These Axsome Therapeutics institutional investors are usually the largest outside holders.
Insider visibility
Axsome Therapeutics insider ownership gives investors a clear signal on alignment. The founder-CEO is the most visible insider, but control is still shared through the board and public votes.
No single controller
Who controls Axsome Therapeutics company ownership? No single outside owner appears to control it. That leaves accountability with the board, proxy votes, and Axsome Therapeutics stockholders.
Why it matters
Public owners get SEC filings, annual meetings, and vote rights. For more on the business side, see Marketing Strategy of Axsome.
Axsome Therapeutics major shareholders are not concentrated in one family or sponsor group. The visible ownership base is centered on Herriot Tabuteau, the board, and large institutions, which is the core of Axsome Therapeutics public float ownership.
Key ownership facts
The Axsome Therapeutics shareholder list is shaped by public-market rules, not private control. Exact percentages move each quarter, but the ownership mix stays clear and disclosed through SEC reports.
- Founder-CEO Herriot Tabuteau stays the key insider
- Public shareholders hold the common stock
- Institutions often rank among top investors
- No outside owner appears to control votes
Axsome SWOT Analysis
- Organized to Save Time on Analysis
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Axsome's Ownership Changed Over Time?
Axsome Therapeutics began as a founder-led biotech and later shifted to public ownership through its 2015 IPO, which changed how control, trust, and accountability are judged. That move broadened the Axsome Therapeutics shareholder base and pushed the story from private science risk to public-market execution.
| Ownership stage | What changed | Why it matters |
|---|---|---|
| Founder-led private phase | Early control stayed close to the founders and core team | Signals mission focus and long-range drug development discipline |
| 2015 IPO | Axsome Therapeutics entered public markets and widened its Axsome Therapeutics stock ownership breakdown | Increased disclosure, market scrutiny, and pressure to deliver milestones |
| Public company phase | Axsome Therapeutics institutional ownership and public float ownership became more important | Trust now depends on reporting quality, growth, and capital use |
Who owns Axsome Therapeutics is best answered through the mix of founder continuity, Axsome Therapeutics insider ownership, and Axsome Therapeutics institutional investors. The clearest ownership signal is that the company still looks founder shaped, but control is now checked by public shareholders, analyst coverage, and the discipline that comes with the market.
Ownership Meaning and Market Control
Axsome Therapeutics ownership matters because it shapes how investors judge credibility, pace, and capital discipline. In CNS drug development, long timelines can make founder continuity look like conviction rather than drift.
- Founder control supports mission-led positioning
- IPO brought public accountability in 2015
- Institutional owners raise execution pressure
- Public float ownership widens market oversight
Axsome Therapeutics major shareholders are best understood through three groups: founders and insiders, institutional holders, and the public float. For readers asking Revenue Streams & Business Model of Axsome, ownership and business model are linked because investors usually reward scientific persistence only when commercial execution starts to match it.
| Stakeholder group | Typical role in Axsome Therapeutics owner structure |
|---|---|
| Insiders | Keep strategic influence and signal conviction |
| Institutions | Provide capital depth and governance pressure |
| Public shareholders | Create liquidity and set market valuation |
Axsome Therapeutics insider trading ownership and Axsome Therapeutics public float ownership matter because they show how much control sits with management versus outside owners. What institutions own Axsome Therapeutics stock is important too, since Axsome Therapeutics institutional ownership often shapes trading volume, voting power, and how quickly the market reacts to results.
Axsome Ansoff Matrix
- Structured to Support Better Decisions
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
Who Sits on Axsome's Board?
Axsome Therapeutics is led by founder-CEO Herriot Tabuteau, and that makes the board of directors central to Axsome Therapeutics ownership and control. There is no dual-class stock, so voting power runs through common shares, board elections, and proxy votes.
| Influence group | How it shapes control | What it means |
|---|---|---|
| Herriot Tabuteau | Founder-CEO and board influence | Strong day-to-day and strategic sway |
| Independent directors | Committee oversight and elections | Can check dilution, pay, and execution |
| Institutional voters | Proxy voting and governance pressure | Can shape director and pay outcomes |
Who owns Axsome Therapeutics is best answered in layers: insiders set the tone, the board sets oversight, and Axsome Therapeutics institutional ownership can swing key votes. For a wider view of the business context, see Target Market of Axsome.
Who holds real influence over Axsome Therapeutics
Axsome Therapeutics stockholders do not face a supervoting control block, so power is shared across common shareholders and directors. In biotech, that gives founder-led judgment real weight, but it also leaves room for outside votes to matter.
- Founder-CEO shapes strategy and risk
- Directors oversee pay and execution
- Institutions affect election outcomes
- Proxy votes can check dilution
Axsome Balanced Scorecard
- Clean, Modern, and Easy to Present
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What Recent Changes Have Shaped Axsome's Ownership Landscape?
Axsome Therapeutics ownership has stayed founder-led, public, and disclosure-heavy through its move into commercial execution. That mix usually supports brand credibility because Axsome Therapeutics shareholders can see quarterly updates, insider activity, and board oversight under Nasdaq rules since 2015.
| Ownership trend | What it signals | Credibility impact |
|---|---|---|
| Public listing since 2015 | Quarterly reporting and SEC oversight | Higher transparency for stockholders |
| Founder-led leadership | Strategic control stays close to management | Can support conviction, but raises governance focus |
| Rising institutional scrutiny | Commercial-stage execution matters more now | Weakens tolerance for dilution or control errors |
The Axsome Therapeutics stock ownership breakdown matters because public biopharma brands trade on trust as much as pipeline data. Axsome Therapeutics institutional ownership and Axsome Therapeutics insider ownership both shape how investors read alignment, control, and risk, especially when the business shifts from development to sales execution. For a broader company context, see Mission, Vision & Core Values of Axsome.
Public ownership raises trust
Axsome Therapeutics owner structure is visible to the market through SEC filings. That makes Axsome Therapeutics ownership details easier to check than for a private biotech.
Founder influence stays important
Who controls Axsome Therapeutics company ownership is less about a parent group and more about board and management influence. That can help focus, but it also puts more weight on oversight.
Institutions want clean execution
Axsome Therapeutics institutional investors usually care about dilution, insider selling, and cash use once a biotech reaches the market. In this phase, the market reads governance as part of the investment case.
Insider alignment is a watch item
Axsome Therapeutics insider trading ownership can support confidence when it stays aligned with long-term value creation. If selling rises or stakes drift lower, investors usually notice fast.
Axsome VRIO Analysis
- Designed for Fast Business Analysis
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What is Customer Demographics and Target Market of Axsome Company?
- What is Sales and Marketing Strategy of Axsome Company?
- What is Growth Strategy and Future Prospects of Axsome Company?
- What is Brief History of Axsome Company?
- How Does Axsome Company Work?
- What is Competitive Landscape of Axsome Company?
- What are Mission Vision & Core Values of Axsome Company?
Frequently Asked Questions
Axsome Therapeutics is owned by public shareholders. It was founded in 2012, went public in 2015, and has no parent company. Founder-CEO Herriot Tabuteau remains the key insider to watch, while institutional investors and other public holders provide most of the voting base through Nasdaq-listed common stock.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.